Striders Impex Ltd

Striders Impex Ltd

₹ 66.8 8.09%
04 Jun - close price
About

Incorporated in 2021, Striders Impex Limited is primarily engaged in the business of licensing, own brand development, and distribution of toys and kids' consumer merchandise.[1]

Key Points

Business Profile[1]
Striders Impex Limited, part of the Striders Group, is engaged in the licensing, distribution, and marketing of toys and kids’ consumer merchandise. The company also focuses on the development of proprietary IP brands and undertakes trading and global distribution operations through its subsidiaries, strengthening its presence in both domestic and international markets.

  • Market Cap 124 Cr.
  • Current Price 66.8
  • High / Low 82.0 / 50.4
  • Stock P/E 26.5
  • Book Value 27.9
  • Dividend Yield 0.00 %
  • ROCE 15.0 %
  • ROE 14.1 %
  • Face Value 10.0

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 35.7%

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost
  • Company has high debtors of 160 days.
  • Working capital days have increased from 65.6 days to 135 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2025 Mar 2026
35.04 40.06
30.75 33.43
Operating Profit 4.29 6.63
OPM % 12.24% 16.55%
0.06 0.02
Interest 0.46 0.97
Depreciation 0.16 0.24
Profit before tax 3.73 5.44
Tax % -1.61% 27.94%
3.79 3.91
EPS in Rs 3,790.00 2.10
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1.99 29.84 41.80 60.53 60.73
1.93 26.72 36.49 51.55 52.29
Operating Profit 0.06 3.12 5.31 8.98 8.44
OPM % 3.02% 10.46% 12.70% 14.84% 13.90%
0.01 0.00 0.07 0.09 0.06
Interest 0.01 0.34 0.76 0.79 1.58
Depreciation 0.00 0.03 0.24 0.32 0.41
Profit before tax 0.06 2.75 4.38 7.96 6.51
Tax % 16.67% 26.18% -0.23% -0.75% 27.96%
0.04 2.03 4.39 8.02 4.70
EPS in Rs 40.00 2,030.00 4,390.00 8,020.00 2.52
Dividend Payout % 0.00% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 27%
TTM: 0%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 32%
TTM: -41%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 39%
3 Years: 36%
Last Year: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.01 0.01 0.01 0.01 18.62
Reserves 0.04 2.07 6.46 14.48 33.35
0.95 4.22 14.66 20.55 20.79
0.41 10.70 8.49 13.81 15.03
Total Liabilities 1.41 17.00 29.62 48.85 87.79
0.00 0.19 0.72 0.82 9.83
CWIP 0.00 0.00 0.00 0.01 0.00
Investments 0.07 0.00 0.00 7.93 0.00
1.34 16.81 28.90 40.09 77.96
Total Assets 1.41 17.00 29.62 48.85 87.79

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-0.23 -2.81 -7.82 3.12 -10.07
-0.07 -0.39 -1.21 -9.21 -3.60
0.95 2.96 9.67 5.19 31.44
Net Cash Flow 0.65 -0.25 0.65 -0.90 17.77
Free Cash Flow -0.23 -3.03 -8.60 2.70 -11.17
CFO/OP -383% -67% -147% 35% -97%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 34.85 91.01 95.79 125.49 159.81
Inventory Days 145.60
Days Payable 97.30
Cash Conversion Cycle 34.85 91.01 95.79 125.49 208.11
Working Capital Days 53.19 21.77 38.42 23.70 134.75
ROCE % 84.66% 37.48% 31.16% 15.01%

Shareholding Pattern

Numbers in percentages

11 Recently
Mar 2026
69.52%
6.90%
1.57%
22.01%
No. of Shareholders 303

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents